drugset / Trial / NCT01651923

PHARMACODYNAMICS ASSESSMENT PRODUCT HEPARIN SODIUM (INTRAVENOUSLY) OF THE SWINE 5.000UI/ML OF BLAU FARMACÊUTICA S/A IN HEALTHY SUBJECTS IN COMPARISON OF SODIUM HEPARIN APP PHARMACEUTICALS

NCT01651923

Phase 1 Unknown 60 enrolled Azidus Brasil
RandomizedCrossoverOpen-labelTreatment

Summary

The objective of this clinical, randomized, crossover, is to assess the pharmacodynamic profile of the drug Heparin Sodium from swine (intravenously), manufactured and marketed by Laboratory Blau Farmacêutica S/A, compared to the product of Heparin Sodium ® company APP Pharmaceuticals, through the determination of activity of the following markers: * Anti-FXa; * Anti-FIIA.

Timeline

Start
2013-02
Primary completion
2013-04
Completion
2013-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Heparin Other / unclassified 5000 iu Intravenous

Indications

No indication recorded.